BridgeBio Pharma (NASDAQ:BBIO) Director Sells $150,579.72 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 2,196 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total value of $150,579.72. Following the sale, the director directly owned 8,383 shares of the company’s stock, valued at $574,822.31. The trade was a 20.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Up 0.8%

Shares of BBIO stock opened at $70.24 on Friday. BridgeBio Pharma, Inc. has a 12 month low of $41.80 and a 12 month high of $84.94. The company has a market cap of $13.76 billion, a PE ratio of -18.78 and a beta of 0.97. The business’s 50 day moving average is $68.88 and its two-hundred day moving average is $71.82.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analyst estimates of $178.07 million. The company’s revenue was up 66.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.88) EPS. As a group, equities analysts expect that BridgeBio Pharma, Inc. will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its position in BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after buying an additional 2,178,556 shares in the last quarter. Farallon Capital Management LLC raised its holdings in BridgeBio Pharma by 9.8% in the 4th quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock valued at $688,292,000 after acquiring an additional 806,463 shares in the last quarter. Aisling Capital Management LP raised its holdings in BridgeBio Pharma by 0.4% in the 3rd quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock valued at $316,294,000 after acquiring an additional 21,486 shares in the last quarter. Invesco Ltd. lifted its position in shares of BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after acquiring an additional 902,648 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of BridgeBio Pharma by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock worth $344,689,000 after purchasing an additional 502,582 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BBIO shares. Canaccord Genuity Group assumed coverage on shares of BridgeBio Pharma in a research report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price for the company. Mizuho lowered their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Royal Bank Of Canada assumed coverage on BridgeBio Pharma in a research note on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective on the stock. Leerink Partners reissued an “outperform” rating and set a $98.00 price objective on shares of BridgeBio Pharma in a research report on Thursday, March 12th. Finally, Barclays restated an “overweight” rating on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. Twenty-one investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $92.90.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.